Asthma Clinical Trial
Official title:
Evaluation of the Written Information Delivered by the General Practitioner of the Patients Presenting to the Emergency Room for an Aggravation of Asthma
Asthma is a common pathology (prevalence 6.4% in 2018, in France), currently managed by the
general practitioner in general practice. It is a chronic disease at risk of exacerbation,
which can lead to the use of care. The treatment of asthma is based on a basic treatment, to
be taken every day, the purpose of which is to avoid acute exacerbations and lead a normal
life. There is also an emergency treatment, to be taken in case of sudden worsening of the
respiratory state. The asthmatic patient is the first actor in his care. He must be able to
react in case of emergency. A good knowledge of the disease and its treatment as well as
training in self-management of crises are thus fundamental and must be part of its medical
care. The existence of an exacerbation represents a criterion of non-control of the disease,
thus a failure of the long-term care of the patient. The optimization of this care includes
individual issues aimed at improving the quality of life and collective by reducing the
avoidable use of care and thus the expenses related to this disease. It relies on therapeutic
education sessions as well as the provision of written information, clear and detailed by the
doctor. This information consists of the writing of a detailed medication prescription as
well as the dispensing of a written action plan.
The action plan must describe the actions to be taken by the patient in case of exacerbation
of his asthma, to regain control. Regarding the format, it can be coupled to the prescription
drug (action plan and prescription on the same prescription) or distinct from the
prescription drug (a prescription for drugs and a prescription for the action plan). In some
countries, "ready-to-use" action plans have been validated by learned societies, which is not
the case today in France. In Canada, a study demonstrated in 2006 that 46% of asthmatic
patients followed in hospital had an action plan, while the national average was estimated at
about 10% in 2010. There is little data in France on the proportion of patients with asthma
action plans.
Unlike the action plan, which is little distributed to the patient, the prescription drug for
asthma is always given to the patient at the end of the consultation and specifies the
procedures for taking treatments.
As part of this work, the investigators are interested in evaluating the written information
given to the adult asthmatic patient by their general practitioner: the action plan but also
the prescription medication.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|